OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 08:41 UTC. Every row links to its source record.

HIP1 huntingtin interacting protein 1

ENSG00000127946 · protein coding · Open Targets profile

Plays a role in clathrin-mediated endocytosis and trafficking (PubMed:11532990, PubMed:11577110, PubMed:11889126). Involved in regulating AMPA receptor trafficking in the central nervous system in an NMDA-dependent manner (By similarity). Regulates presynaptic nerve terminal activity (By similarity). Enhances androgen receptor (AR)- mediated transcription (PubMed:16027218). May act as a proapoptotic protein that induces cell death by acting through the intrinsic apoptosis pathway (PubMed:11007801). Binds 3-phosphoinositides (via ENTH domain) (PubMed:14732715). May act through the ENTH domain to promote cell survival by stabilizing receptor tyrosine kinases following ligand-induced endocytosis (PubMed:14732715). May play a functional role in the cell filament networks (PubMed:18790740). May be required for differentiation, proliferation, and/or survival of somatic and germline progenitors (PubMed:11007801, PubMed:12163454). {ECO:0000250|UniProtKB:Q8VD75, ECO:0000269|PubMed:11007801, ECO:0000269|PubMed:11532990, ECO:0000269|PubMed:11577110, ECO:0000269|PubMed:11889126, ECO:0000269|PubMed:12163454, ECO:0000269|PubMed:14732715, ECO:0000269|PubMed:16027218, ECO:0000269|PubMed:18790740, ECO:0000269|PubMed:9147654}.

In 15 of 15 cancers, the evidence for HIP1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751lung carcinomalung carcinomalung carcinoma: somatic 0.61pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61pancreatic neuroendocrine tumorpancreatic neuroendocrine tumorpancreatic neuroendocrine tumor: somatic 0.61HER2 positive breast carcinomaHER2 positive breast carcinomaHER2 positive breast carcinoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61undifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.4404999911785126 (upper bound 0.5415199995040894). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of HIP1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of HIP1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.